959 Vaccination Outcomes in Inflammatory Bowel Disease

Abdallah, Jason; Anna, Kiran; Hassan, Tuyyab; Jain, Alok

doi:10.1016/s0016-5085(14)60601-6

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Application of the inclusion and exclusion criteria yielded 150 unique studies for analysis [ 45 – 194 ]. Fig 1 shows the yields at each stage of the review.…”

Section: Resultsmentioning

confidence: 99%

The full benefits of adult pneumococcal vaccination: A systematic review

et al. 2017

View full text Add to dashboard Cite

BackgroundPneumococcal disease causes substantial morbidity and mortality, including among adults. Adult pneumococcal vaccines help to prevent these burdens, but they are underused. Accounting for the full benefits of adult pneumococcal vaccination may promote more rational resource allocation decisions with respect to adult pneumococcal vaccines.ObjectivesUsing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a systematic review to assess the extent to which the literature has empirically captured (e.g., through measurement or modeling) the full benefits of adult pneumococcal vaccination.MethodsWe systematically searched PubMed and Embase to identify studies published between January 1, 2010 and April 10, 2016 that examine adult pneumococcal vaccination. We included articles if they captured any health or economic benefit of an adult pneumococcal vaccine administered to adults age ≥ 50 or ≥ 18 in risk groups. Finally, we summarized the literature by categorizing the types of benefits captured, the perspective taken, and the strength of the evidence presented. Our protocol is number 42016038335 in the PROSPERO International prospective register of systematic reviews.ResultsWe identified 5,857 papers and included 150 studies for analysis. While most capture health gains and healthcare cost savings, far fewer studies consider additional benefit categories, such as productivity gains. However, the studies with a broader approach still exhibit significant limitations; for example, many present only abstracts, while others offer no new measurements. Studies that examine the 13-valent pneumococcal conjugate vaccine focus more on broad economic benefits, but still have limitations.ConclusionsThis review highlights the need for more robust empirical accounting of the full benefits of adult pneumococcal vaccination. Literature outside this realm indicates that these broad benefits may be substantial. Failing to investigate the full benefits may lead society to undervalue vaccines' contributions and therefore underinvest in their development and adoption.

show abstract

“…Application of the inclusion and exclusion criteria yielded 150 unique studies for analysis [ 45 – 194 ]. Fig 1 shows the yields at each stage of the review.…”

Section: Resultsmentioning

confidence: 99%

The full benefits of adult pneumococcal vaccination: A systematic review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…According to the Centers for Disease Control and Prevention guidelines, patients on immunosuppressive medications should be vaccinated once with pneumococcal conjugate vaccine, followed by pneumococcal polysaccharide vaccine after 8 weeks, a second dose of the same 5 years later, and then a third dose after 65 years [68]. A recent study indicated that among vaccinated IBD individuals, there was a 9-fold decrease in the incidence of influenza and an 8-fold decrease in the incidence of pneumonia [69]. Vaccination for hepatitis B is an important part of management of IBD patients.…”

Section: Introductionmentioning

confidence: 99%

Care of inflammatory bowel disease patients in remission

Subramanian

Triadafilopoulos

2016

Gastroenterol. Rep.

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) comprises two distinct conditions: ulcerative colitis and Crohn’s disease, both of which are chronic, relapsing disorders carrying significant morbidity, mortality and healthcare costs. With growing attention to coordinated healthcare for patients with chronic systemic diseases, this review focuses on the care of IBD patients in remission, their concerns, quality of life, follow-up, the role of primary care physicians and the IBD-specific aspects of long-term care. We did an extensive PubMed search for articles pertaining to IBD patients in remission and, along with the authors’ experience, formulated a comprehensive review. The difficulties faced by IBD patients in remission include but are not limited to education and employment concerns, psychosocial issues, problems related to health insurance, nutrition, fertility and infections. This review also addresses newer treatment modalities, the debatable effects of smoking on IBD and the importance of vaccination. IBD in remission can be a challenge due to its multifaceted nature; however, with a coordinated approach by gastroenterologists and other involved practitioners, several of these issues can be addressed.

show abstract